GST HG 171
Alternative Names: GST-HG-171Latest Information Update: 19 Oct 2023
Price :
$50 *
At a glance
- Originator Fujian Cosunter Pharmaceutical
- Class Antivirals
- Mechanism of Action 3C viral protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID-19 pneumonia
- Phase I COVID 2019 infections
Most Recent Events
- 07 Aug 2023 Fujian Akeylink Biotechnology completes a phase I trial (In volunteers) in China (PO) (NCT06087055)
- 14 Jul 2023 Fujian Akeylink Biotechnology completes a phase-II/III trial in COVID-19 pneumonia in China (PO) (NCT05656443)
- 12 May 2023 Fujian Akeylink Biotechnology initiates a phase I trial (In volunteers) in China (PO) (NCT06087055)